Cargando…
The safety profile of favipiravir should not be the first argument to suspend its evaluation in viral hemorrhagic fevers
Autores principales: | Malvy, Denis, Taburet, Anne-Marie, de Lamballerie, Xavier, Mentre, France, Extramiana, Fabrice |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7316222/ https://www.ncbi.nlm.nih.gov/pubmed/32584817 http://dx.doi.org/10.1371/journal.pntd.0008259 |
Ejemplares similares
-
The number of cases, mortality and treatments of viral hemorrhagic fevers: A systematic review
por: Belhadi, Drifa, et al.
Publicado: (2022) -
Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted
por: Nguyen, Thi Huyen Tram, et al.
Publicado: (2017) -
Modeling Favipiravir Antiviral Efficacy Against Emerging Viruses: From Animal Studies to Clinical Trials
por: Madelain, Vincent, et al.
Publicado: (2020) -
High doses of favipiravir in two men survivors of Ebola virus disease carrying Ebola virus in semen in Guinea
por: Eloy, Philippine, et al.
Publicado: (2022) -
Clinical Management of Argentine Hemorrhagic Fever using Ribavirin and Favipiravir, Belgium, 2020
por: Veliziotis, Ioannis, et al.
Publicado: (2020)